Skip to main content

FDA Approvals

Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors

Lisa A. Raedler, PhD, RPh

Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation

Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Lisa A. Raedler, PhD, RPh

Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer

Breast Cancer, FDA Approvals, In the News, Oncology

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Oncology

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

FDA Approvals, In the News, Lung Cancer, Oncology

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

FDA Approvals, In the News

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Page 14 of 21
Results 131 - 140 of 202